PM
PCRX icon

Prosight Management’s Pacira BioSciences PCRX Stock Holding History

Prosight Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-94,362
Closed -$2.76M – 54
2024
Q1 		$2.76M Sell
94,362
-164,062
-63% -$5.04M 0.77% 33
2023
Q4 		$8.72M Sell
258,424
-951,953
-79% -$27.9M 3.63% 11
2023
Q3 		$37.1M Buy
1,210,377
+332,791
+38% +$12M 11.77% 1
2023
Q2 		$35.2M Buy
877,586
+786,463
+863% +$32.5M 10.29% 1
2023
Q1 		$3.72M Buy
+91,123
New +$3.63M 1.78% 24
2020
Q3 		– Sell
-55,000
Closed -$2.89M – 57
2020
Q2 		$2.89M Buy
+55,000
New +$2.3M 1.43% 26

Other funds holding PCRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $34.9B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return